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Abstract
Current technologies for visualizing infectious pathways of viruses rely on fluorescent labeling of
capsid proteins by chemical conjugation or genetic manipulation. For non-invasive in vivo imaging
of such agents in mammalian tissue, we engineered bioluminescent Gaussia luciferase-tagged
Adeno-Associated Viral (gLuc/AAV) vectors. The enzyme was incorporated into recombinant AAV
serotype 1, 2, and 8 capsids by fusion to the N-terminus of the VP2 capsid subunit to yield
bioluminescent virion shells. The gLuc/AAV vectors were utilized to quantify kinetics of cell surface
binding by AAV2 capsids in vitro. Bioluminescent virion shells displayed an exponential decrease
in luminescent signal following cellular uptake in vitro. A similar trend was observed following
intramuscular injection in vivo, although the rate of decline in bioluminescent signal varied markedly
between AAV serotypes. While gLuc/AAV1 and gLuc/AAV8 vectors displayed rapid decrease in
bioluminescent signal to background levels within 30 min, the signal from gLuc/AAV2 vectors
persisted for over 2 hrs. Bioluminescent virion shells might be particularly useful in quantifying
dynamics of viral vector uptake in cells and peripheral tissues in live animals.
Adeno-Associated Viral (AAV) vectors have recently gained popularity in gene transfer
applications due to the availability of a vector toolkit comprised of several serotypes and
variants exhibiting diverse tissue tropisms (1). Tracking the in vivo biodistribution and tissue
tropisms of AAV vectors is critical towards understanding their infectious pathways and
establishing safety for human gene transfer applications. Fusion constructs of viral capsid
subunits and fluorescent proteins, such as GFP, have had a tremendous impact as reagents for
elucidating infectious pathways of viruses in vitro through confocal microscopy techniques
(2,3). However, such fluorescence-based imaging techniques for tracking viral vectors in live
animals might not be feasible in light of the low vector concentrations (doses range from
109-1012 particles; pico-femtomolar range), high background auto-fluorescence and resulting
weak signal-to-background ratio in vivo (4,5). Radioisotope-based imaging techniques are
perhaps ideally suited for such in vivo studies (6), although significant challenges pertaining
to radiochemical labeling of viruses and subsequent access to radio-imaging technology remain
to be addressed.
The current, most widely utilized modality for understanding viral vector tropism in vivo is to
monitor expression levels/patterns of a luciferase reporter gene incorporated into the vector
genome using live animal bioluminescence imaging (7). The latter approach, while somewhat
informative of vector tissue tropisms, cannot be utilized to accurately predict dynamics of
vector dissemination from or vector uptake at the site of administration. To address these issues,
we have developed a simple strategy that involves a viral capsid-luciferase fusion protein,
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which when incorporated into the AAV capsid during production results in generation of
bioluminescent AAV shells that can be monitored using live animal imaging.
The AAV capsid is comprised of three viral protein subunits, Vp1, Vp2 and Vp3 (8). While
Vp1 and Vp3 are critical for forming infectious virions, Vp2 is thought to be redundant. Further,
the N-terminus of Vp2 can tolerate fusion with large proteins such as GFP (~30kDa), thereby
allowing incorporation and surface display of non-endogenous viral proteins on the AAV
capsid (2). Using the latter strategy, we engineered Gaussia luciferase (gLuc; 19kDa), a highly
sensitive luciferase (9,10), onto the N-terminus of the Vp2 protein derived from the AAV2
capsid sequence. Briefly, the gLuc transgene was amplified from the plasmid pGLuc
(Nanolight, Pinetop, AZ) by PCR using primers (AGTACTATATA; GATATAGATAGAG)
flanked by EagI and MluI sites and PCR product ligated into pVp2AGFP following restriction
digestion to generate pVp2AgLuc. Bioluminescent gLuc/AAV1; gLuc/AAV2 and gLuc/
AAV8 capsids packaging the GFP transgene driven by the CMV promoter were generated as
per the schematic shown in Figure 1. The pXR-ACA and pVp2AGFP plasmids, in which the
Vp2 start site has been mutated from ACG to ACA and ATG, respectively have been described
previously (11,2). Vector genome-containing particles were purified by cesium chloride
density ultracentrifugation, dialyzed against PBS and viral titers determined using dot blot as
described earlier (12). Genomic titers of gLuc/AAV vectors displayed an inverse correlation
to the ratio of pVp2AgLuc to pXR-ACA plasmids utilized in transfection, with ratios of 25:75
or lower yielding genomic titers comparable to that of recombinant AAV vectors (~1012 vector
genome-containing particles/mL). These results are in agreement with those described by
Warrington et al., (2004) for AAV capsids containing similar Vp2-GFP fusion proteins (2).
Bioluminescence of (109) viral particles was determined using 50μL of coelenterazine substrate
(CLZ, 40μg/mL) in 0.1M Tris buffer (pH 7.5) containing 0.6M NaCl with a Victor2®
bioluminescence plate reader (Perkin Elmer). As shown in Figure 2, transfection of a 10:90
ratio of plasmids pVp2gLuc:pXR-ACA afforded gLuc/AAV2 capsids with a high
bioluminescent signal (A) without adversely affecting transduction efficiency (B) or viral titer
(data not shown). Transduction experiments were carried out with HEK293 cells using an MOI
of 1000 and GFP transgene expression monitored 24hr post-transduction using fluorescence
microscopy. Higher levels of incorporation of the gLuc-Vp2 fusion construct into AAV capsids
(plasmid ratio 25:75 or higher) resulted in decreased viral titer or low transduction efficiency
(data not shown). Based on these results, gLuc/AAV vectors utilized for all further analysis
were generated using a pVp2AgLuc-to-pXRACA plasmid ratio of 10:90, previously
established to minimally impact titer and transduction efficiency.
The gLuc/AAV capsids were first evaluated as potential reagents for quantifying cell surface
binding and uptake events. Briefly, HelaS3 cells maintained in suspension culture as per ATCC
recommendations, were incubated at 4°C for different time intervals with (a) gLuc/AAV2
capsids and (b) gLuc/AAV2 capsids pre-incubated with heparin for 1hr on ice (30μg/mL,
Sigma) at an MOI of 10000. For binding studies, 106 cells were spun down, the cell pellet
washed thrice with cold 1×PBS and luminometric assays with CLZ substrate (40μg/mL) carried
out as described earlier. As shown in Figure 3A, gLuc/AAV2 capsids display saturable binding
to the surface of HelaS3 cells. Preincubation with heparin reduced the number of cell surface-
bound viral particles by 4-5 fold, corroborating the use of heparan sulfate by gLuc/AAV2 as
the primary receptor (13). The total number of cell surface-bound viral particles was determined
to be ~700 per HelaS3 cell and peak binding levels achieved 2hrs post-incubation at 4°C.
For cellular uptake studies, HelaS3 cells were incubated with gLuc/AAV2 capsids for 2hrs at
4°C, pelleted, washed three times with DMEM containing 10%FBS and incubated at 37°C to
allow internalization. Cells (107) were removed at different time points, lysed using passive
lysis buffer (Promega) and bioluminescence quantified using CLZ substrate as described
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earlier. As shown in Figure 3B, gLuc/AAV2 capsids display a rapid exponential decline in
signal reaching near-background levels within 1hr. This rapid decline can potentially be
explained by competitive inhibition of gLuc by coelenteramide, the oxidized form of
coelenterazine (10) or inactivation of enzymatic activity of gLuc by proteolysis within
endosomes. Further, it is likely that irreversible conformational changes in AAV capsid
proteins during the course of entry might attribute to inactivation of luciferase activity. Similar
decline in bioluminescent signal has been observed during cellular uptake of retroviral particles
containing firefly luciferase fused to the C-terminal of the envelope protein (14). Taken
together, the aforementioned results corroborate the use of bioluminescent AAV capsids as
sensitive reporters of the kinetics of cell surface binding and uptake of AAV vectors.
Having established the utility of gLuc/AAV capsids in vitro, we focused our attention on live
animal imaging studies. Different gLuc/AAV serotypes were administered through
intravenous (tail vein) and intramuscular (gastrocnemius) routes in mice. In particular, we
chose AAV1, which is known to transduce skeletal muscle with high efficiency (15); AAV2,
being the most well-characterized AAV serotype with modest tropism for liver and muscle
(16); and AAV8, which has been shown to transduce skeletal muscle as well liver with high
efficiency (17).
For monitoring the dynamics of AAV vectors following intramuscular injection, CLZ (5mg/
kg) dissolved in methanol/PBS was first injected into the tail vein of female Balb/C mice (4-6
weeks old) followed immediately by injection of gLuc/AAV capsids (dose 5×1010 particles)
of serotypes 1, 2 or 8 into skeletal muscle in the left hind limb. Images were obtained at 5min,
10min, 30min, 1hr and 2hrs post-administration using the Xenogen IVIS 100® imaging system.
As seen in Figures 4A-C, gLuc/AAV capsids are clearly detectable at the site of injection.
Interestingly, gLuc/AAV8 capsids appear detectable in liver 5min post-administration (Figure
4C) supporting previous studies that AAV8 can traverse through the blood vessel wall and
distribute to peripheral tissues (17). As shown in Figure 4D, the decrease in bioluminescent
signal over time at the site of intramuscular injection corroborates results seen with in vitro
studies in general. In particular, light output from gLuc/AAV2 vectors in skeletal muscle
appears to decrease to background levels at a slower rate (> 2 hrs) in comparison with gLuc/
AAV1 or gLuc/AAV8 vectors (30 min). Such differential kinetics might be explained by (a)
a potentially faster rate of skeletal muscle cell uptake by AAV1/AAV8 in comparison with
AAV2 and/or (b) differential rate of dissemination of AAV capsids from the site of
administration. The latter explanation is particularly likely given the potential for AAV2 to
adhere to heparan sulfate proteoglycans, abundantly expressed on the surface of fast and slow
twitch muscle fibers (18). Such avid binding could in turn, attenuate dissemination of AAV2
capsids from the site of injection. Similar observations have been made with regard to
dissemination of different AAV serotypes in the brain (19,20).
The tracking of intravenously administered gLuc/AAV capsids was precluded by lack of
sensitivity possibly arising from low concentrations of bioluminescent AAV virions in various
tissues and the resulting low signal-to-background ratios (data not shown). It is likely that such
studies might be possible with larger doses of viral capsids (1012-1013/mouse), currently only
attainable through large scale production.
In summary, Gaussia luciferase-labeled AAV capsids were successfully demonstrated as
useful reagents for quantifying cell surface binding and uptake in vitro. More importantly,
gLuc/AAV virion shells were detectable using live animal bioluminescence imaging in skeletal
muscle. Using these reagents, we were able to demonstrate that AAV2 capsids might
disseminate from the site of injection at a slower rate in comparison with AAV1 or AAV8.
Alternatively, it is likely that the cellular uptake of AAV1/8 occurs at a rate faster than that of
AAV2 capsids in skeletal muscle cells. Similar observations have been made with regard to
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the uptake and transcytosis of different AAV serotypes in epithelial cells (21). Studies focused
on delineating the underlying mechanism(s) are currently in progress. The studies described
herein also highlight the potential advantages of live animal tracking of viral vectors in
comparison with methods that would require large numbers of animals and QPCR in obtaining
pharmacokinetic/biodistribution data. It is noteworthy to mention that dual luciferase-based
imaging studies can be carried out using gLuc/AAV capsids packaging a firefly luciferase
(fLuc) cassette due to different substrate specificities of the two luciferase proteins. The
relatively smaller MW and higher sensitivity of Gaussia luciferase (19kDa) in comparison to
firefly luciferase (61kDa) offers a significant advantage for incorporation into capsid proteins
of enveloped or non-enveloped viruses in general (14,22). Bioluminescent virion shells could
serve as useful tools for understanding the biology of AAV vectors in peripheral organs,
especially the eye and the brain.
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Schematic featuring transfection protocol for production of bioluminescent AAV capsids.
Plasmids pVp2gLuc and pXR-ACA are transfected at indicated ratios (total 10μg/15cm plate)
along with helper Ad genes (pXX6-80) and packaging construct (pTR-GFP) in HEK 293 cells
as described previously (13). Bioluminescent virion shells are generated when the Vp2gLuc
protein is incorporated into AAV capsids containing Vp1 and Vp3 proteins at endogenous
levels.
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Functional characterization of gLuc/AAV capsids generated by transfecting 0:100; 5:95 or
10:90 ratio of plasmids pVp2gLuc and pXR2ACA. (A) Light emission from gLuc/AAV2
capsids was quantified using a Victor2® plate reader following incubation of viral fractions
with coelenterazine (CLZ, 40μg/mL) substrate in 0.1M Tris buffer containing 0.6M NaCl.
Average values from two different viral preparations is shown. (B) Representative fluorescence
micrographs of GFP transgene expression in HEK293 cells obtained at 24hrs post-transduction
with AAV2-GFP vectors (MOI 1000) containing different levels of Vp2gLuc.
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Cell surface binding and uptake assays with gLuc/AAV2 capsids. (A) HelaS3 cells were
incubated with gLuc/AAV2 particles (filled dots) or gLuc/AAV2 particles pre-incubated with
heparin (open dots) at an MOI 10,000 at 4°C in DMEM containing 10% FBS. Aliquots of
106 cells were removed at different time intervals and cell-associated bioluminescence
quantified using CLZ substrate as described earlier. (B) HelaS3 cells pre-incubated with gLuc/
AAV2 particles (MOI 10,000) for 2hrs at 4°C were pelleted, washed and incubated in DMEM-
FBS at 37°C. Aliquots of 107 cells were removed at different time intervals, lysed and cell-
associated bioluminescence quantified using CLZ substrate as described above. All
experiments were performed in triplicate. Error bars represent standard deviations.
Asokan et al. Page 8














Quantitative live animal imaging of bioluminescent gLuc/AAV capsid dynamics in Balb/C
mice following intramuscular administration. Representative bioluminescent images of mice
obtained using a Xenogen IVIS 100® system at 5min, 10min, 30min and 1hr post-IM
administration of 5×1010 of (A) gLuc/AAV2; (B) gLuc/AAV1 and (C) gLuc/AAV8 vectors.
Mice received an intravenous (tail vein) dose of 5mg/kg CLZ in MeOH/PBS immediately
before IM injection gLuc/AAV particles. Light emission pseudocolor scales (total photons/
sec/cm2) are shown to left of each panel. (D) Quantitation of the kinetics of light emission from
left hind limb region of each mouse after IM administration of different gLuc/AAV capsids.
All experiments were performed in triplicate. Error bars represent standard deviations.
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